Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COLUMN
Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
Philip Carrigan Morunda asked numerous long-term expatriates in Japan’s pharmaceutical industry for suggestions for new executives coming to Japan or new companies looking to establish themselves in the world’s second-largest pharmaceutical market. Interviewing candidates is difficult, but when you add…
To read the full story
COLUMN
- Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
March 27, 2026
- The Strategic MSL: Beyond Data Delivery, It’s About Impact
February 19, 2026
- AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential
January 27, 2026
- AI: Your New HR BFF (Not Your Replacement!)
December 24, 2025
- AI in HR: Navigating the Ethical Minefield
November 28, 2025
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…